Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVX-301 CSF biomarker study in adults with depression on stable SSRI or SNRI therapy
ACTRN12625000876493Phase 2Completed
- Sponsor
- Evecxia Therapeutics
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of EVX-301 in major depressive disorder (MDD) (2 arms), sponsored by Evecxia Therapeutics. Primary endpoints: Safety and tolerability of single 24-hour EVX-301 infusion and CSF biomarker effect of EVX-301. Started Jan 2026; status: completed.
02
Drugs
EVX-301
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12625000876493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000876493.